Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy
- 31 July 2004
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 40 (10), 1502-1508
- https://doi.org/10.1016/j.ejca.2004.03.014
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcomeBritish Journal of Cancer, 2003
- Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapyThe Lancet, 2002
- Pathobiology of preoperative chemotherapyCancer, 2002
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapyEuropean Journal Of Cancer, 2000
- First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)British Journal of Cancer, 1999
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.Journal of Clinical Oncology, 1998
- Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapyBritish Journal of Cancer, 1997
- Clinical and pathological response to primary chemotherapy in operable breast cancerEuropean Journal Of Cancer, 1997